Ibuprofen use is associated with reduced C-reactive protein and interleukin-6 levels in chronic spinal cord injury.
Ibuprofen use is associated with reduced C-reactive protein and interleukin-6 levels in chronic spinal cord injury.
复制标题
布洛芬的使用与慢性脊髓损伤中 C 反应蛋白和白细胞介素 6 水平降低有关。
DOI：
10.1080/10790268.2020.1773029
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Morse,LeslieR
中科院分区：
文献类型：
--
作者：
Park,Andrew;Anderson,Dustin;Battaglino,RicardoA;Nguyen,Nguyen;Morse,LeslieR
目的：评估慢性脊髓损伤（SCI）患者使用布洛芬与全身炎症生物标志物C-反应蛋白（CRP）和白细胞介素-6（IL-6）之间的相关性。研究设计：前瞻性队列研究。设置：社区居住的SCI患者。参与者：338名（278名男性，60名女性）社区居住的慢性SCI患者（损伤后≥1年）。干预措施：无。主要结局指标：通过超灵敏ELISA测定定量CRP和IL-6水平。一般线性模型被用来评估各种临床和人口统计学因素和CRP和IL-6 level.Results之间的关联：有50个活跃的布洛芬用户和288个非用户。调整后的临床和人口因素，布洛芬用户有显着较低的CRP水平（2.3毫克/升与3.5毫克/升，P = 0.04）和IL-6水平（3.2 pg/ml与4.0 pg/ml，P = 0.04）相比nonusers.Conclusions：我们的研究表明，自我报告的布洛芬使用可能与CRP和IL-6水平在慢性SCI后，调整已知的混杂因素，并建议布洛芬的使用可能是一个重要的，潜在的变量，考虑在未来的研究集中在SCI全身炎症。 未来的前瞻性研究需要评估布洛芬对慢性SCI患者全身炎症标志物的频率、持续时间和剂量依赖性作用。这些发现可能支持未来的临床试验，以确定布洛芬治疗慢性SCI各种结局的安全性和有效性。
Objective:To assess the association between ibuprofen use and the systemic inflammatory biomarkers C-reactive protein (CRP) and interleukin-6 (IL-6) in chronic Spinal Cord Injury (SCI).Study design:Prospective cohort study.Setting:Community dwelling individuals with SCI.Participants:338 (278 male, 60 female) community dwelling individuals with chronic SCI (≥1-year post-injury).Interventions:None.Main outcome measures:CRP and IL-6 levels were quantified by ultra-sensitive ELISA assay. General linear models were used to assess associations between various clinical and demographic factors and CRP and IL-6 levels.Results:There were 50 active ibuprofen users and 288 non-users. After adjusting for clinical and demographic factors, ibuprofen users had significantly lower CRP levels (2.3 mg/L versus 3.5 mg/L, P = 0.04) and IL-6 levels (3.2 pg/ml versus 4.0 pg/ml, P = 0.04) compared to nonusers.Conclusions:Our study suggests that self-reported ibuprofen use may be negatively associated with CRP and IL-6 levels in chronic SCI after adjusting for known confounding factors, and suggests ibuprofen use may be an important, potential variable to consider in future studies focused on systemic inflammation in SCI. Future prospective studies require assessing frequency, duration, and dosage-dependent effects of ibuprofen on systemic markers of inflammation in chronic SCI. These findings may support future clinical trials to determine safety and efficacy of ibuprofen treatment for various outcomes in chronic SCI.